Curated News
By: NewsRamp Editorial Staff
June 18, 2025
NanoViricides' NV-387 Shows Promise Against COVID Variants and Bird Flu
TLDR
- NanoViricides, Inc.'s NV-387 offers a strategic advantage by outperforming leading antivirals in animal models, positioning it as a frontrunner in addressing COVID-19 variants and Bird Flu.
- NV-387 mimics heparan sulfate structures, targeting an invariant viral binding mechanism, which minimizes viral escape and enhances its broad-spectrum antiviral efficacy.
- NV-387's potential for rapid patient recovery and natural immunity advancement could significantly improve global health outcomes amidst evolving viral threats.
- Discover how NanoViricides' NV-387, a groundbreaking oral antiviral, is set to revolutionize treatment for COVID-19 variants and Bird Flu with its unique mechanism.
Impact - Why it Matters
The development of NV-387 by NanoViricides represents a significant advancement in the fight against viral infections, offering a potential solution to the limitations of current vaccine-dependent strategies. Its broad-spectrum capability and oral administration could revolutionize treatment protocols for COVID-19, Bird Flu, and other respiratory viruses, providing faster recovery and immunity. This news is crucial for healthcare professionals, patients, and investors alike, as it opens new avenues for antiviral therapy and pandemic preparedness.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has announced that its antiviral candidate, NV-387, is uniquely positioned to combat emerging COVID-19 variants such as NB1.8.1 'Nimbus' and evolving strains of Bird Flu. Having completed Phase I trials without adverse events, NV-387 is an oral, broad-spectrum antiviral that mimics heparan sulfate structures, making viral escape unlikely. The company reports that NV-387 outperformed leading antivirals like Remdesivir, Tamiflu(R), and Xofluza in animal models of lethal lung infections. NanoViricides highlights its U.S.-based cGMP manufacturing readiness and the potential of NV-387 to offer rapid patient recovery and natural immunity, bypassing the limitations of vaccine-dependent strategies. For more details, visit the full press release.
NanoViricides is a development-stage company specializing in nanomaterials for antiviral therapy, with NV-387 as its lead drug candidate aimed at treating RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections. The company is advancing NV-387 into Phase II human clinical trials and is also developing NV-HHV-1 for Shingles treatment. For further information, visit www.NanoViricides.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Shows Promise Against COVID Variants and Bird Flu
